Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2023 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth/expansion, with the company already embedded, and the trajectory early and large. Key elements from transcript: - Vyleesi: management discusses growth, but also mentions licensees: Fosun Pharma (China) reported first sale in Hainan; Kwangdong Pharmaceuticals (South Korea) completed enrollment in Phase III trial, data expected by year-end, potential regulatory submission. This is about partners' progress. Also UpScriptHealth partnership for telemedicine, anticipating reach increasing. - The company's own programs: dry eye, ulcerative colitis, kidney disease, erectile dysfunction combination, glaucoma. These are internal development programs, not counterparties' scaling. - The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? The forward account includes partner activities (Fosun, Kwangdong, UpScript) but these are relatively minor compared to the overall pipeline. The main forward drivers are internal clinical trials and data readouts. The Vyleesi licensing partners are mentioned, but the company's own growth is also driven by its own commercial efforts. The counterparties' trajectories are not the dominant explanation; the company's own programs are. Also, the company is not already embedded in those partners' growth in a way that the demand is settled; the partners are advancing their own trials and sales, but the company's revenue from them is not yet significant. The company's own Vyleesi sales are direct. The partners are licensees, but the company's forward story is not primarily about their scaling. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.